{"created":"2023-06-20T15:50:32.818835+00:00","id":3356,"links":{},"metadata":{"_buckets":{"deposit":"26d5b21e-292a-4395-9e04-6cf1820ac363"},"_deposit":{"created_by":18,"id":"3356","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"3356"},"status":"published"},"_oai":{"id":"oai:redcross.repo.nii.ac.jp:00003356","sets":["99:64:117"]},"author_link":["47","211","48","8085"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2006-03-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"17","bibliographicPageStart":"12","bibliographicVolumeNumber":"11","bibliographic_titles":[{"bibliographic_title":"徳島赤十字病院医学雑誌"},{"bibliographic_title":"Tokushima Red Cross Hospital Medical Journal ","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"低adiponectin 血症を呈する2型糖尿病に対するインスリン抵抗性改善薬pioglitazone の血糖コントロールならびに血清adiponectin 濃度への影響を検討した．対象は血清adiponectin 濃度が４μg/ml 未満の２型糖尿病患者５例である．全例男性で，年齢50±17歳（Mean±SD），BMI 27.8±5.6kg/m2．併用薬の内訳は，α GI1例，SU＋α GI2例，Glinide＋Insulin1例であった．4例は高血圧，高脂血症を合併し，1例に虚血性心疾患があった．Pioglitazone 投与前のPPG209±53mg/dl，HbA1C8.6±1.3％，血漿IRI6.3±3.4μU/m（l n＝4），尿中CPR96±25μg／日（n＝4），血清adiponectin3.0±1.0μg/ml，血清leptin5.4±3.2ng/ml であった．Pioglitazone15～30mg／日を投与後，血清adiponectin 濃度は4例で速やかに上昇し，1例（症例4）のみ不変であった（前3.0±1.0μg/ml → 後9.2±6.3μg/ml）．全例で血糖コントロールの改善が得られ，6ヶ月後のHbA１C7.3±1.0％であった．症例により血圧や脂質代謝の軽度の改善も認められた．肥満が高度であったBMI30kg/m２以上の２例では，体重増加や血清leptin 値の上昇が見られ，2例とも3ヶ月以降の血糖コントロール改善は鈍化または悪化した．低adiponectin 血症患者へのpioglitazone の投与は，速やかな血清adiponectin 濃度の上昇により大血管障害リスクの一つを減少させるが，血糖コントロール改善の維持には，体重増加や血清leptin 値の上昇をきたさない生活習慣の継続が重要と考えられた．","subitem_description_type":"Abstract"}]},"item_10002_heading_23":{"attribute_name":"見出し","attribute_value_mlt":[{"subitem_heading_banner_headline":"原著","subitem_heading_language":"ja"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"徳島赤十字病院"}]},"item_10002_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"徳島赤十字病院"}],"subitem_relation_type_id":{}}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1346-9878 ","subitem_source_identifier_type":"ISSN"}]},"item_10002_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"金崎, 淑子"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"新谷, 保実"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"守家, 慈子"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2013-05-03"}],"displaytype":"simple","filename":"trchmj1101_12-17.pdf","filesize":[{"value":"744.6 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"pdf002136","url":"https://redcross.repo.nii.ac.jp/record/3356/files/trchmj1101_12-17.pdf"},"version_id":"ab0eb496-8105-4584-8e57-2d8d51f85685"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"２型糖尿病","subitem_subject_scheme":"Other"},{"subitem_subject":"pioglitazone","subitem_subject_scheme":"Other"},{"subitem_subject":"adiponectin","subitem_subject_scheme":"Other"},{"subitem_subject":"leptin","subitem_subject_scheme":"Other"},{"subitem_subject":"type 2 diabetes","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"pioglitazone","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"adiponectin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"leptin","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"低Adiponectin血症を呈する2型糖尿病患者に対するPioglitazoneの有用性の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"低Adiponectin血症を呈する2型糖尿病患者に対するPioglitazoneの有用性の検討"},{"subitem_title":"Evaluation of the Usefulness of Pioglitazone in Type ２ Diabetes Patients Presenting with Hypoadiponectinemia","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"18","path":["117"],"pubdate":{"attribute_name":"公開日","attribute_value":"2013-05-03"},"publish_date":"2013-05-03","publish_status":"0","recid":"3356","relation_version_is_last":true,"title":["低Adiponectin血症を呈する2型糖尿病患者に対するPioglitazoneの有用性の検討"],"weko_creator_id":"18","weko_shared_id":18},"updated":"2023-06-20T22:02:33.417965+00:00"}